Table 1 Baseline characteristics of patients with secondary platinum-sensitive relapse
| Â | Study Group (n = 71) | Control Group (n = 48) | p-value |
|---|---|---|---|
Age at diagnosed (years) | |||
 ≤49 years | 42 (59.2%) | 25(52.1%) | 0.446 |
 >49 years | 29 (40.8%) | 23(47.9%) |  |
BRCA-germline-mutation status | |||
 BRCA1 mutation | 54 (76.1%) | 38 (79.2%) | 0.691 |
 BRCA2 mutation | 17 (23.9%) | 10 (20.8%) |  |
NAC-IDS | |||
 Yes | 14 (19.7%) | 10 (20.8%) | 0.882 |
 No | 57 (80.3%) | 38 (79.2%) |  |
FIGO stage at diagnosed | |||
 I/II | 12 (16.9%) | 5 (10.4%) | 0.321 |
 III/IV | 59 (83.1%) | 43 (89.6%) |  |
Primary tumor location | |||
 Ovary | 69 (97.2%) | 47 (97.9%) | 0.802 |
 Fallopian tube | 2 (2.8%) | 1 (2.1%) |  |
Histologic type | |||
 High-grade serous | 68 (95.8%) | 44(91.7%) | 0.483 |
 Serous not specified | 1 (1.4%) | 2 (4.2%) |  |
 Endometrioid | 2 (2.8%) | 1 (0.0%) |  |
 Clear-cell | 0 (0.0%) | 1 (2.1%) |  |
Residual lesions | |||
 No | 31 (43.7%) | 19 (39.6%) | 0.770 |
 Yes | 20 (28.2%) | 14 (29.2%) |  |
 Unknowna | 20 (28.2%) | 15 (31.3%) |  |
PFI after 1st line of platinum-containing chemotherapy | |||
 <12 months | 24 (33.8%) | 15 (31.3%) | 0.771 |
 ≥12 months | 47 (66.2%) | 33 (68.8%) |  |
PFI after 2nd line of platinum-containing chemotherapy | |||
 ≥6, <12 months | 52 (73.2%) | 29 (60.4%) | 0.141 |
 ≥12 months | 19 (26.8%) | 19 (39.6%) |  |
CA-125 level at secondary platinum-sensitive relapse | |||
 ≤70 U/ml | 18 (25.4%) | 8 (16.7%) | 0.677 |
 >70 U/ml | 50 (70.4%) | 18 (37.5%) |  |
 Unknowna | 3 (4.2%) | 22 (45.8%) |  |
Tumor response of 3rd line | |||
 PR/CR | 55 (77.5%) | 28 (58.3%) | 0.766 |
 SD/PD | 16 (22.5%) | 7 (14.6%) |  |
 Unknowna | 0 (0.0%) | 13 (27.1%) |  |
Duration of PARPi treatment | |||
 <6 months | 7 (9.9%) | -- | -- |
 ≥6, <12 months | 32 (45.1%) | -- |  |
 ≥12 months | 32 (45.1%) | -- |  |
Hematological toxicity (≥ 3 CTCAE) | |||
 Yes | 31 (43.7%) | -- | -- |
 No | 36 (50.7%) | -- |  |
 Unknowna | 4 (5.6%) | -- |  |
Chemotherapy regimens of 3rd line | |||
 Carboplatin based | -- | 16 (33.3%) | -- |
 Nedaplatin based | -- | 10 (20.8%) |  |
 Cisplatin based | -- | 5 (10.4%) |  |
 Oxaliplatin based | -- | 1 (2.1%) |  |
 Lobaplatin based | -- | 7 (14.6%) |  |
 Multiple platinum | -- | 9b (18.8%) |  |